Natural product chemistry and anticancer drug discovery

Cancer Drug Design and Discovery

Volumn , Issue , 2008, Pages 107-130

  Huryn, Donna M ^a   Wipf, Peter ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66049156993     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369448-5.50008-2     Document Type: Chapter

References (122)

1. Akinaga S., Gomi K., Morimoto M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 1991, 51:4888-4892.
2. Altmann K.-H. Recent developments in the chemical biology of epothilones. Curr. Pharm. Des. 2005, 11:1595-1613.
3. Altmann K.-H., Floerscheimer A., O'Reilly T., Wartmann M. The natural products epothilones A and B as lead structures for anti-cancer drug discovery: chemistry, biology, and SAR studies. Progress Med. Chem. 2004, 42:171-205.
4. Andersen R.J., Coleman J.E., Piers E., Wallace D.J. Total synthesis of (-)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity. Tetrahedron Lett. 1997, 38:317-320.
5. Andrus M.B., Meredith E.L., Simmons B.L. Total synthesis of (+)-geldanamycin and (-)-o-quinogeldanamycin with use of asymmetric anti- and syn- glycoate aldol reactions. Org. Lett. 2002, 4:3549-3552.
6. Andrus M.B., Meredith E.L., Hicken E.J. Total synthesis of (+)-geldanamycin and (-)-o-quinogeldanamycin: asymmetric glycolate aldol reactions and biological evaluation. J. Org. Chem. 2003, 68:8162-8169.
7. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 2006, 5:493-506.
8. Beisler J.A., Abbasi M.M., Driscoll J.S. Synthesis and anti-tumor activity of 5-azacytosine arabinoside. J. Med. Chem. 1979, 22:1230-1234.
9. Boehm M.F., Zhang L., Badea B.A. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 1994, 37:2930-2941.
10. Bollag D.M., McQueney P.A., Zhu J. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55:2325-2333.
11. Buzdar A.U., Robertson J.F.R. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann. Pharmacother. 2006, 40:1572-1583.
12. Buzdar A.U., Robertson J.F.R., Eiermann W., Nabholtz J.-M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002, 95:2006-2016.
13. Cassady J.M., Chan K.K., Foss H.G., Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm. Bull. 2004, 52:1-26.
14. Chang Z., Sitachitta N., Rossi J.V. Biosynthetic pathway and gene cluster analysis of curacin A, an antitubulin natural product from the tropical marine Cyanobacterium Lyngbya majuscula. J. Natural Prod. 2004, 67:1356-1367.
15. Chari R.V., Martell B.A., Gross J.L. Immunoconjugates containing novel maytansinoids: promising anti-cancer drugs. Cancer Res. 1992, 52:127-131.
16. Choueiri T.K., Wesolowski R., Mekhail T.M. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr. Oncol. Rep. 2006, 8:104-107.
17. Coleman J.E., da Silva E.D., Kong F. Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 1995, 51:10653-10662.
18. Daiss J.O., Burschka C., Mills J.S. Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disilaanalogue of the RXR-selective retinoid agonist bexarotene. Organometallics 2005, 24:3192-3199.
19. Damle N.K., Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Pharmacol. 2003, 3:386-390.
20. Danishefsky S.J., Shair M.D. Observations in the chemistry and biology of cyclic enediyne antibiotics: total syntheses of calicheamicin γ1 and dynemicin A. J. Org. Chem. 1996, 61:16-44.
21. da Rocha A.B., Lopes R.M., Schwartsmann G. Natural products in anti-cancer therapy. Curr. Op. Pharmacol. 2001, 1:364-369.
22. de Boer C., Meulman P.A., Wnuk R.J., Peterson D.H. Geldanamycin, a new anti biotic. J. Antibiot. 1970, 23:442-447.
23. Drysdale M.J., Brough P.A., Massey A. Targeting HSP90 for the treatment of cancer. Curr. Opin. Drug Discov. Dev. 2006, 9:483-495.
24. Du W. Towards new anti-cancer drugs: a decade of advances in synthesis of camptothecins and related alkaloids. Tetrahedron 2003, 59:8649-8687.
25. Egorin M.J., Lagattuta T.F., Hamburger D.R. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. 2002, 49:7-19.
26. Eldridge G.R., Vervoort H.C., Lee C.M. High-throughput method for the production and analysis of large natural product libraries for drug discovery. Analyt. Chem. 2002, 74:3963-3971.
27. Elkabani M., List A.F. Management of transfusion-dependent myelodysplastic syndromes: current and emerging strategies. Am. J. Cancer 2006, 5:71-80.
28. Elmore S.W., Oost T.K., Park C.-M. Inhibitors of antiapoptotic proteins for cancer therapy. Annu. Rep. Med. Chem. 2005, 40:245-262.
29. Elnakady Y.A., Sasse F., Lunsdorf H., Reichenbach H. Disorazol A1, a highly effective antimitotic agent acting on tubulin polymerization and inducing apoptosis in mammalian cells. Biochem. Pharmacol. 2004, 67:927-935.
30. Fuerstner A. Chemistry and biology of roseophilin and the prodigiosin alkaloids: a survey of the last 2500 years. Angew. Chem. Intl Ed. 2003, 42:3582-3603.
31. Fuse E., Kuwabara T., Sparreboom A. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J. Clin. Pharmacol. 2005, 45:394-403.
32. Gamble W.R., Durso N.A., Fuller R.W. Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg. Med. Chem. 1999, 7:1611-1615.
33. Garcia-Carbonero R., Supko J.G. Current perspectives on the clinical experience pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 2002, 8:641-661.
34. Gerth K., Bedorf N., Hoefle G. Antibiotics from gliding bacteria. 74. Epothilones A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antiobiot. 1996, 49:560-563.
35. Gong H., Xie W. Orphan nuclear receptors, PXR and LXR: new ligands and therapeutic potential. Expert Opin. Ther. Targets 2004, 8:49-54.
36. Hamann P.R., Hinman L.M., Hollander I. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for the treatment of acute myeloid leukemia. Bioconjug. Chem. 2002, 13:47-58.
37. Hamann P.R., Hinman L.M., Beyer C.F. An anti-CD33 antibody-calicheamicin conjugate for the treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 2002, 13:40-46.
38. Hamann P.R., Upeslacis J., Borders D.B. Enediynes. Anticancer Agents from Natural Products 2005, 451-474. CRC Press, Boca Raton. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
39. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacy Therapeut. 1992, 55:31-51.
40. Hardt I.H., Steinmetz H., Gerth K. New natural epothilones from Sorangium cellulosum, strains So cd90/B2 and So cd90/D13: isolation, structure elucidation, and SAR studies. J. Natural Prod. 2001, 64:847-856.
41. Hoefle G., Bedorf N., Steinmetz H. Epothilone A and B- novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure and conformation in solution. Angew Chem. Intl Ed. Engl. 1996, 35:1567-1569.
42. Hollingshead M., Alley M., Burger A.M. In vivo anti-tumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxylgeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmcol. 2005, 56:115-125.
43. Hollosy F., Keri G. Plant-derived protein tyrosine kinase inhibitors as anti-cancer agents. Curr. Med. Chem. 2004, 4:173-197.
44. Hoshino I., Matsubara H., Hanari N. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin. Cancer Res. 2005, 11:7945-7952.
45. Howell A. The future of fulvestrant ("Faslodex"). Cancer Treatment Rev. 2005, 31:S26-S33.
46. Howell A., Abram P. Clinical development of fulvestrant ("Faslodex"). Cancer Treatment Rev. 2005, 31:S3-S9.
47. Issa J.-P.J., Kantarjian H.M., Kirkpatrick P. Fresh from the pipeline: azacytidine. Nat. Rev. Drug Discov. 2005, 4:275-276.
48. Janin Y.L. Heat shock protein 90 inhibitors. A textbook example of medicinal chemistry?. J. Med. Chem. 2005, 48:7503-7512.
49. Jez J.M., Chen J.C.-H., Rastelli G. Crystal structure and molecular modeling of 17-DMAG in complex with human HSP90. Chem. & Biol. 2003, 10:361-368.
50. Jiang X.-R., Walter Sowell J., Zhu B.T. Synthesis of 7α-substituted derivatives of 17betaestradiol. Steroids 2006, 71:334-342.
51. Jones P.A. Altering gene expression with 5azacytidine. Cell 1985, 40:485-486.
52. Khalil M.W., Sasse F., Luensdorf H. Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. Chem. Biochem. 2006, 7:678-683.
53. Kim D.-K., Lee N. Recent advances in topoisomerase I-targeting agents, camptothecin analogues. Mini Rev. Med. Chem. 2002, 2:611-619.
54. Kingston D.G., Newman D.J. The search for novel drug leads for predominately anti-tumor therapies by utilizing mother nature's pharmacophoric libraries. Curr. Opin. Drug Discov. Dev. 2005, 8:207-227.
55. Kolman A. Epothilone D. Curr. Opin. Invest. Drugs 2004, 5:657-667.
56. Komoda Y., Kishi T. Anti-cancer agents based on natural product models, Maytansinoids. Med. Chem. 1980, 16:353-389.
57. Kupchan S.M., Komoda Y., Court W.A. Maytansine, a novel antileukemic ansa marolide from Maytenus ovatus. J. Am. Chem. Soc. 1972, 94:1354-1356.
58. Lee M.D., Dunne T.S., Siegel M.S. Calichemicins, a novel family of antitumor antibiotics. 1 Chemistry and partial structure of calichemicin γ1. J. Am. Chem. Soc. 1987, 109:3463-3466.
59. Lee M.D., Dunne T.S., Chang C.C. Calichemicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calicheamicin γ1. J. Am. Chem. Soc. 1987, 109:3466-3468.
60. Li K.W., Wu J., Xing W., Simon J.A. Total synthesis of the antitumor depsipeptide FR-901,228. J. Am. Chem. Soc. 1996, 118:7237-7238.
61. Lombardi P. Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim. Biophys. Acta Mol. Basis Dis. 2002, 1587:326-337.
62. Lopez-Lazaro M. Flavonoids as anti-cancer agents: structure-activity relationship study. Curr. Med. Chem. Anti-Cancer Agents 2002, 2:691-714.
63. Losiewicz M.D., Carlson B.A., Kaur G. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8273. Biochem. Biophys. Res. Commun. 1994, 201:589-595.
64. Manderville R.A. Synthesis, proton-affinity and anti-cancer properties of the prodigiosin-group natural products. Curr. Med. Chem. Anti-Cancer Agents 2001, 1:195-218.
65. Miyata Y. HSP90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr. Pharm. Des. 2005, 11:1131-1138.
66. Montaner B., Perez-Tomas R. The prodigiosins: a new family of anti-cancer drugs. Curr. Cancer Drug Targets 2003, 3:57-65.
67. Nagle A., Hur W., Gray N.S. Antimitotic agents of natural origin. Curr. Drug Targets 2006, 7:305-326.
68. Nicolaou K.C., Smith A.L., Yue E.W. Chemistry and biology of natural and designed enediynes. Proc. Natl. Acad. Sci. USA 1993, 90:5881-5888.
69. Newman D.J., Cragg G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Natural Prod. 2004, 67:1216-1238.
70. Newman D.J., Cragg G.M. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr. Med. Chem. 2004, 11:1693-1713.
71. Newman D.J., Cragg G.M., Snader K.M. Natural products as sources of new drugs over the period 1981-2002. J. Natural Prod. 2003, 66:1022-1037.
72. Nicolaou K.C., Roschangar F., Vourloumis D. Chemical biology of epothilones. Angew. Chem. Intl Ed. 1998, 37:2014-2045.
73. Niedballa U., Vorbrueggen H. Synthesis of nucleosides. 13. General synthesis of N-glycosides. V. Synthesis of 5-azacytidines. J. Org. Chem. 1974, 39:3672-3673.
74. Nieman J.A., Coleman J.E., Wallace D.J. Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. J. Natural Prod. 2003, 66:183-199.
75. Okada T., Tanaka K., Nakatani F. Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Intl J. Cancer 2006, 118:90-97.
76. Patel K., Piagentini M., Rascher A. Engineered biosynthesis of geldanamycin analogs for HSP90 inhibition. Chem. Biol. 2004, 11:1625-1633.
77. Poruchynsky M.S., Kim J.-H., Nogales E. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry 2004, 43:13944-13954.
78. Prudhomme M. Staurospoines and structurally related indolocarbazoles as antitumor agents. Anticancer Agents Natural Prod. 2005, 499-517.
79. Rapoport H., Holden K.G. The synthesis of prodigiosin. J. Am. Chem. Soc. 1962, 84:635-642.
80. Ravi M., Zask A., Rush T.S. Structurebased identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry 2005, 44:15871-15879.
81. Rawat D.S., Joshi M.C., Joshi P., Atheaya H. Marine peptides and related compounds in clinical trial. Anti-Cancer Agents Med. Chem. 2006, 6:33-40.
82. Remillard S., Rebhun L.I., Howie G.S., Kupchan S.M. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975, 189:1002-1005.
83. Ren W., Qiao Z., Wang H. Flavonoids: promising anti-cancer agents. Med. Res. Rev. 2003, 23:519-534.
84. Rivkin A., Chou T.-C., Danishefsky S.J. On the remarkable antitumor properties of fludelone: how we got there. Angew. Chem. Intl Ed. 2005, 44:2838-2850.
85. Roe S.M., Prodromou C., O'Brien R. Structural basis for inhibition of the HSP90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42:260-266.
86. Sausville E.A. Cyclin-dependent kinase modulators studied at the NCI: preclinical and clinical studies. Curr. Med. Chem. Anti-Cancer Agents 2003, 3:47-56.
87. Sausville E.A. Cell cycle regulatory kinase modulators: interim progress and issues. Curr. Topics Med. Chem. 2005, 5:1109-1117.
88. Sausville E.A., Tomaszewski J.E., Ivy P. Clinical development of 17-allylamino,17-demethoxygeldanamycin. Curr. Cancer Drug Targets 2003, 3:377-383.
89. erbB-2in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 1995, 38:3806-3812.
90. Seimbille Y., Benard F., van Lier J.E. Synthesis of 16α-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. J. Chem. Soc. Perkin Trans. 2002, 1:2275-2281.
91. Smith V., Sausville E.A., Camalier R.F. Comparison of 17-dimethylaminoethylamino17-demethoxy-geldanamycin (17DMAG) and 17allylamino-17-demethyoxygeldanamycin (17AAG) in vitro: effects on HSP90 and client proteins in melanoma models. Cancer Chemother. Pharm. 2005, 56:126-137.
92. Sriram D., Yogeeswari P., Thirumurugan R., Bal T.R. Camptothecin and its analogues: a review on their chemotherapeutic potential. Natural Prod. Res. 2005, 19:393-412.
93. Stebbins C.E., Russo A.A., Schneider C. Crystal structure of an HSP90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239-250.
94. Takahashi I., Kobayashi E., Asano K. UCN-01, a selective inhibitor of protein kinase C from streptomyces. J. Antibiotics (Tokyo) 1987, 40:1782-1784.
95. Talpir R., Benayahu Y., Kashman Y. Hemiasterlin and geodiamolide-TA - 2 new cytotoxic peptides from the marine sponge hemiasterellaminor (kirkpatrick). Tetrahedron Lett. 1994, 35:4453.
96. Tanaka J., Trianto A., Musman M. New polyoxygenated steroids exhibiting reversal of multidrug resistance from the gorgonian Isis hippuris. Tetrahedron 2002, 58:6259-6266.
97. Thomas C.J., Rahier N.J., Hecht S.M. Camptothecin: current perspectives. Bioorg. Med. Chem. 2004, 12:1585-1604.
98. Thorson J.S., Sievers E.L., Ahlert J. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharm. Des. 2000, 6:1841-1879.
99. Tian Z.-Q., Liu Y., Zhang D. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg. Med. Chem. 2004, 12:5317-5329.
100. Uckun F.M., Narla R.K., Zeren T. In vivo toxicity, pharmacokinetics, and anti-cancer activity of genistein linked to recombinant human epidermal growth factor. Clin. Cancer Res. 1998, 4:1125-1134.
101. Uckun F.M., Naria R.K., Jun X. Cytotoic activity of epidermal growth factor-genisein against breast cancer cells. Clin. Cancer Res. 1998, 4:901-912.
102. Uehara Y. Natural product origins of HSP90 inhibitors. Curr. Cancer Drug Targets 2003, 3:325-330.
103. src in rat kidney cells infected with Rouse Sarcoma virus. Mol. Cell Biol. 1986, 6:2198-2206.
104. Ulukan H., Swaan P.W. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002, 62:2039-2057.
105. Vedejs E., Kongkittingham C. A total synthesis of (-)-hemiasterlin using N-Bts methodology. J. Org. Chem. 2001, 7355-7364.
106. Wall M.E., Wani M.C., Cooke C.E. Plant antitumor agents I: the isolation and structure of camptothecin, a novel alkoloidal leukemia and tumor inhibitor from camptotheca accuminata. J. Am. Chem. Soc. 1966, 88:3888-3890.
107. Wang Z., McPherson P.A., Raccor B.S. et al., Structureactivity and high-content imaging analyses of novel tubulysins. Chem. Biol. Drug Design 70, 75-86.
108. Wasserman H.H., McKeon J.E., Smith L., Forgione P. Prodigiosin, structure and partial synthesis. J. Am. Chem. Soc. 1960, 82:506-507.
109. Watkins E.B., Chittiboyina A.G., Jung J.-C., Avery M.A. The epothilones and related analogues - a review of their syntheses and anti-cancer activities. Curr. Pharm. Des. 2005, 11:1615-1653.
110. Whitesell L., Linduist S.L. HSP90 and the chaperoning of cancer. Natl Rev. Cancer 2005, 5:761-772.
111. vsrc heteroprotein complex formation by benzo quinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91:8324-8328.
112. Widdison W.C., Wilhelm S.D., Cavanagh E.E. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49:4392-4408.
113. Winkley M.W., Robins R.K. Direct glycosylation of 1,3,5-triazinones. New approach to the synthesis of the nucleoside antibiotic 5-azacytidine (4-amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2one) and related derivatives. J. Org. Chem. 1970, 35:491-495. and references cited therein.
114. Wolpert-Defilippes M.K., Adamson R.H., Cysyk R.L., Jones D.G. Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide. Biochem. Pharmacol. 1975, 24:751-754.
115. Yamashita A., Norton E.B., Kaplan J.A. Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. Bioorg. Med. Chem. Lett. 2004, 14:5317-5322.
116. Zask A., Birnberg G., Cheung K. D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors. Bioorg. Med. Chem. Lett. 2004, 14:4353-4358.
117. Zask A., Kaplan J., Musto S., Loganzo F. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. J. Am. Chem. Soc. 2005, 127:17667-17671.
118. Zein N., Sinha A.M., McGahren W.J., Ellestad G.A. Calicheamicin γ1: an antitumor antibiotic that cleaves double-stranded dna site specifi cally. Science 1988, 240:1198-1200.
119. Zein N., Poncin M., Nilakantan R., Ellestad G.A. Calicheamicin γ1 and DNA: molecular recognition process responsible for site-specificity. Science 1989, 244:697-699.
120. Zein N., McGahren W.J., Morton G.O. Exclusive abstraction of nonexchangeable hydrogens from DNA by calicheamicin γ1. J. Am. Chem Soc. 1989, 111:6888-6890.
121. Zhai D., Jin C., Satterthwaite A.C., Reed J.C. Comparison of chemical inhibitors of antiapoptotic Bcl-2 family proteins. Cell Death Diff. 2006, 13:1419-1421.
122. Zhai S., Senderowicz A.M., Sausville E.A., Figg W.D. Flavopiridol, a novel cyclinc-dependent kinase inmhibitor, in clinical development. Ann. Pharmacol. 2002, 36:905-911.